Preview

Войти

Регистрация нового пользователя Забыли Ваш пароль?

Кардиология

Расширенный поиск

Тиазидные и тиазидоподобные диуретики в терапии артериальной гипертензии

https://doi.org/10.18087/cardio.2019.11.2653

Полный текст:

PDF (Rus)

Аннотация

Статья представляет собой аналитический обзор клинических исследований, посвященных эффективности и безопасности тиазидных и тиазидоподобных диуретиков (ТД) в лечении пациентов с артериальной гипертензией. В работе проводится сопоставление роли диуретиков в современных клинических рекомендациях по контролю артериального давления, оцениваются метаболические эффекты ТД в сравнительном аспекте.

Об авторах

Я. А. Орлова
ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова»
Россия
Москва


Н. В. Курлыкина
ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова»
Россия
Москва


Е. М. Середенина
ФГБОУ ВО «Московский государственный университет им. М. В. Ломоносова»
Россия
Москва


Список литературы

1. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В., Карпов Ю.А., Белоусов Ю.Б. и др. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010;3:5–26

2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–248. DOI: 10.1016/j.jacc.2017.11.006

3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339

4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta­analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665–b1665. DOI: 10.1136/bmj.b1665

5. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials. Archives of Internal Medicine. 2005;165(12):1410–9. DOI: 10.1001/archinte.165.12.1410

6. Turnbull F. Effects of different blood­pressure­lowering regimens on major cardiovascular events: results of prospectively­designed overviews of randomised trials. The Lancet. 2003;362(9395):1527–35. DOI: 10.1016/S0140­6736(03)14739­3

7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High­Risk Hypertensive Patients Randomized to Angiotensin­Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid­Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA: The Journal of the American Medical Association. 2002;288(23):2981–97. DOI: 10.1001/jama.288.23.2981

8. Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which Interventions Offer Best Value for Money in Primary Prevention of Cardiovascular Disease? PLoS ONE. 2012;7(7):e41842. DOI: 10.1371/journal.pone.0041842

9. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH et al. Health Outcomes Associated With Various Antihypertensive Therapies Used as First­Line Agents: A Network Meta­analysis. JAMA. 2003;289(19):2534–44. DOI: 10.1001/jama.289.19.2534

10. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):1028–34. PMID: 4862069

11. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–52. PMID: 4914579

12. Helgeland A, Leren P. Oslo Study: Treatment of Mild Hypertension. Nephron. 1987;47(1):108–10. DOI: 10.1159/000184565

13. Materson BJ, Cushman WC, Goldstein G, Reda DJ, Freis ED, Ramirez EA et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension (Dallas, Tex.: 1979). 1990;15(4):348–60. PMID: 2318517

14. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High­Risk Patients. New England Journal of Medicine. 2008;359(23):2417–28. DOI: 10.1056/NEJMoa0806182

15. Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ et al. Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24­Hour Ambulatory Systolic Blood Pressure Control. Hypertension. 2011;57(2):174–9. DOI: 10.1161/HYPERTENSIONAHA.110.159939

16. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. Journal of the American College of Cardiology. 2011;57(5):590–600. DOI: 10.1016/j.jacc.2010.07.053

17. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid­lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967–75. PMID: 10789664

18. Siragy HM. Major outcomes in high­risk hypertensive patients randomized to angiotensin­converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). Current Hypertension Reports. 2003;5(4):293–4. PMID: 12844462

19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64. PMID: 2046107

20. Ames RichardP, Hill P. Increase in serum­lipids during treatment of hypertension with chlorthalidone. The Lancet. 1976;307(7962):721–3. DOI: 10.1016/S0140­6736(76)93093­2

21. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR et al. Influence of long­term, low­dose, diuretic­based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Archives of Internal Medicine. 1998;158(7):741–51. PMID: 9554680

22. Kreeft JH, Langlois S, Ogilvie RI. Comparative trial of indapamide and hydrochlorothiazide in essential hypertension, with forearm plethysmography. Journal of Cardiovascular Pharmacology. 1984;6(4):622–6. PMID: 6206316

23. Brandao SA, Izar MC, Fischer SM, Santos AO, Monteiro CM, Povoa RM et al. Early Increase in Autoantibodies Against Human Oxidized Low­Density Lipoprotein in Hypertensive Patients After Blood Pressure Control. American Journal of Hypertension. 2010;23(2):208–14. DOI: 10.1038/ajh.2009.214

24. Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 2000;7(1):32–7. PMID: 10822211

25. PATS Collaborating Group. Post­stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal. 1995;108(9):710–7. PMID: 8575241

26. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358(18):1887–98. DOI: 10.1056/NEJMoa0801369

27. Агеева Н.В., Агеев Ф.Т., Орлова Я.А., Хеймец Г.И., Рогоза А.Н. Влияние тиазидных диуретиков на артериальное давление, реологию крови и жесткость сосудистой стенки у пациентов с АГ: результаты исследования РОНДО (РеОлогические и аНгиопротекторное Действие прОлонгированного индапамида у больных с артериальной гипертонией). Болезни сердца и сосудов. 2008;1:30­5

28. Mironneau J, Savineau J­P, Mironneau C. Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. European Journal of Pharmacology. 1981;75(2–3):109–13. DOI: 10.1016/0014­2999(81)90068­6

29. Kooter AJ, Smulders YM. Chlorthalidone better than hydrochlorothiazide in hypertension. Nederlands Tijdschrift Voor Geneeskunde. 2010;154:A1608. PMID: 20456766

30. Tziomalos K, Athyros VG, Mikhailidis DP, Karagiannis A. Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension. Current Pharmaceutical Design. 2013;19(21):3766–72. PMID: 23286433

31. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide Versus Chlorthalidone: Evidence Supporting Their Interchangeability. Hypertension. 2004; 43 (1): 4–9. DOI: 10.1161/01.HYP.0000103632.19915.0E

32. Beaumont K, Vaughn DA, Fanestil DD. Thiazide diuretic drug receptors in rat kidney: identification with [3H]metolazone. Proceedings of the National Academy of Sciences. 1988;85(7):2311–4. DOI: 10.1073/pnas.85.7.2311

33. Sumiye L, Vivian AS, Frisof KB, Podany EC. Potassium loss associated with hydrochlorothiazide versus chlorthalidone. Clinical Therapeutics. 1981;4(4):308–20. PMID: 7332917

34. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta­Analysis of Dose­Response Relationships for Hydrochlorothiazide, Chlorthalidone, and Bendroflumethiazide on Blood Pressure, Serum Potassium, and Urate. Hypertension. 2012;59(6):1104–9. DOI: 10.1161/HYPERTENSIONAHA.111.190637

35. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated MetaAnalytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure: Clinical Drug Investigation. 2007;27(11):735–53. DOI: 10.2165/00044011­200727110­00001

36. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressurelowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database of Systematic Reviews. 2014;5:CD003824. DOI: 10.1002/14651858.CD003824.pub2

37. Amery A, Bulpitt C, Schaepdryver AD, Fagard R, Hellemans J, Mutsers A et al. Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. The Lancet. 1978;311(8066):681–3. DOI: 10.1016/S0140­6736(78)90797­3

38. Chrysant SG, Neller GK, Dillard B, Frohlich ED. Effects of Diuretics On Lipid Metabolism in Patients With Essential Hy per tension. Angiolog y. 1976;27(12):707–11. DOI: 10.1177/000331977602701205

39. Pollare T, Lithell H, Berne C. A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension. New England Journal of Medicine. 1989;321(13):868–73. DOI: 10.1056/NEJM198909283211305

40. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. New England Journal of Medicine. 2000;342(13):905–12. DOI: 10.1056/NEJM200003303421301

41. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo­Scandinavian Cardiac Outcomes Trial­Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. The Lancet. 2005;366(9489):895–906. DOI: 10.1016/S0140­6736(05)67185­1

42. Fletcher A, Amery A, Birkenhäger W, Bulpitt C, Clement D, de Leeuw P et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension. 1991;9(3):225–30. PMID: 1851785

43. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension­2 study. The Lancet. 1999;354(9192):1751–6. DOI: 10.1016/S0140­6736(99)10327­1

44. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T et al. Outcomes With Nifedipine GITS or Co­Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hy per tension. 2003;41(3):431–6. D OI: 10.1161/01.HYP.0000057420.27692.AD

45. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 2002;359(9311):995–1003. DOI: 10.1016/S0140­6736(02)08089­3

46. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long­term effect of diuretic­based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. The American Journal of Cardiology. 2005;95(1):29–35. DOI: 10.1016/j.amjcard.2004.08.059

47. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR et al. Long­Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. Circulation: Cardiovascular Quality and Outcomes. 2012;5(2):153–62. DOI: 10.1161/CIRCOUTCOMES.111.962522

48. Zhang X, Zhao Q. Association of Thiazide­Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta­Analysis of Randomized Controlled Clinical Trials. The Journal of Clinical Hypertension. 2016;18(4):342–51. DOI: 10.1111/jch.12679

49. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, CooperDeHoff RM et al. Lack of Correlation Between Thiazide­Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Pharmacotherapy. 2009;29(10):1157–65. DOI: 10.1592/phco.29.10.1157

50. Kobalava ZD, Kotovskaya YV, Moiseev VS. Efficacy and Acceptability of Indapamide Sustained Release in Elderly HighRisk Hypertensive Patients: the ARGUS Study. High Blood Pressure & Cardiovascular Prevention. 2008;15(4):275–82. DOI: 10.2165/0151642­200815040­00007

51. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304(6824):405–12. DOI: 10.1136/bmj.304.6824.405

52. Elliott WJ, Weber RR, Murphy MB. A double­blind, randomized, placebo­controlled comparison of the metabolic effects of low dose hydrochlorothiazide and indapamide. Journal of Clinical Pharmacology. 1991;31(8):751–7. PMID: 1880234

53. Kieboom BCT, Zietse R, Ikram MA, Hoorn EJ, Stricker BH. Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population. Pharmacoepidemiology and Drug Safety. 2018;27(11):1166–73. DOI: 10.1002/pds.4636

54. Mychka V.B., Chazova I.E. Russian evidence­based medicine – MINOTAUR program: advantages of the retard form of indapamide in the treatment of metabolic syndrome. Consilium Medicum. 2006;8(5):46–50. [Russian: Мычка В.Б., Чазова И.Е. Российская доказательная медицина – программа МИНОТАВР: преимущества ретардной формы индапамида при лечении метаболического синдрома. Consilium Medicum. 2006;8(5):46­50]

55. Ernst ME, Moser M. Use of Diuretics in Patients with Hypertension. New England Journal of Medicine. 2009;361(22):2153–64. DOI: 10.1056/NEJMra0907219

56. Reid IR, Ames RW, Orr­Walker BJ, Clearwater JM, Horne AM, Evans MC et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. The American Journal of Medicine. 2000;109(5):362–70. DOI: 10.1016/S0002­9343(00)00510­6

57. LaCroix AZ. Low­Dose Hydrochlorothiazide and Preservation of Bone Mineral Density in Older Adults: A Randomized, Double­Blind, Placebo­Controlled Trial. Annals of Internal Medicine. 2000;133(7):516–26. DOI: 10.7326/0003­4819­133­7­200010030­00010

58. Schoofs MWCJ, van der Klift M, Hofman A, de Laet CEDH, Herings RMC, Stijnen T et al. Thiazide Diuretics and the Risk for Hip Fracture. Annals of Internal Medicine. 2003;139(6):476–82. DOI: 10.7326/0003­4819­139­6­200309160­00010

59. Ayvazian JH, Ayvazian LF. A study of the hyperuricemia induced by hydrochlorothiazide and acetazolamide separately and in combination. Journal of Clinical Investigation. 1961;40(11):1961–6. DOI: 10.1172/JCI104421

60. Leemhuis MP, Struyvenberg A. Significance of hypokalaemia due to diuretics. The Netherlands Journal of Medicine. 1973;16(1):18–28. PMID: 4572424

61. Weidmann P. Metabolic Profile of Indapamide Sustained­Release in Patients with Hypertension: Data from Three Randomised Double­Blind Studies. Drug Safety. 2001;24(15):1155–65. DOI: 10.2165/00002018­200124150­00006

62. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. Journal of Hypertension. 2000;18(10):1465–75. PMID: 11057435

63. Wu S, Sun L, Zhao H, Wang G, Li Y, Wang L et al. Chronic effects of low­dose hydrochlorothiazide in patients with mild to moderate essential hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(5):396–9. PMID: 16776948

64. Ames RP, Hill P. Elevation of serum lipid levels during diuretic therapy of hypertension. The American Journal of Medicine. 1976;61(5):748–57. DOI: 10.1016/0002­9343(76)90156­X

65. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: The case for low­dose diuretics. The American Journal of Medicine. 1996;101(3):83S­92S. DOI: 10.1016/S0002­9343(96)00271­9

66. Ott SM, LaCroix AZ, Ichikawa LE, Scholes D, Barlow WE. Effect of Low­Dose Thiazide Diuretics on Plasma Lipids: Results from a Double­Blind, Randomized Clinical Trial in Older Men and Women. Journal of the American Geriatrics Society. 2003;51(3):340–7. DOI: 10.1046/j.1532­5415.2003.51107.x

67. Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS – A Randomized Double­Blind Trial. Stroke. 2004;35(12):2807–12. DOI: 10.1161/01.STR.0000147041.00840.59

68. Pottegård A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. Journal of Internal Medicine. 2017;282(4):322–31. DOI: 10.1111/joim.12629

69. Pottegård A, Pedersen SA, Schmidt SAJ, Hölmich LR, Friis S, Gaist D. Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Internal Medicine. 2018;178(8):1120–2. DOI: 10.1001/jamainternmed.2018.1652

70. Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Sørensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population­based case–control study. British Journal of Cancer. 2008;99(9):1522–8. DOI: 10.1038/sj.bjc.6604686

71. Schmidt SAJ, Schmidt M, Mehnert F, Lemeshow S, Sørensen HT. Use of antihypertensive drugs and risk of skin cancer. Journal of the European Academy of Dermatology and Venereology. 2015;29(8):1545–54. DOI: 10.1111/jdv.12921

72. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004;363(9426):2022–31. DOI: 10.1016/S0140­6736(04)16451­9

73. Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Ekbom T, Wester P­O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP­Hypertension). The Lancet. 1991;338(8778):1281–5. DOI: 10.1016/0140­6736(91)92589­T

74. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta­analysis of randomised trials. BMJ. 2008;336(7653):1121–3. DOI: 10.1136/bmj.39548.738368.BE

75. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. ­London: Royal College of Physicians (UK); 36 p.

76. Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K et al. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Heart and Vessels. 2013;28(3):316–22. DOI: 10.1007/s00380­012­0246­5

77. Hamada T, Mizuta E, Kondo T, Hirai M, Yamada K, Kato M et al. Effects of a low­dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung. 2011;60(02):71–5. DOI: 10.1055/s­0031­1296251

78. Okin PM, Hille DA, Kjeldsen SE, Lindholm LH, Edelman JM, Dahlof B et al. Greater Regression of Electrocardiographic Left Ventricular Hypertrophy During Hydrochlorothiazide Therapy in Hypertensive Patients. American Journal of Hypertension. 2010;23(7):786–93. DOI: 10.1038/ajh.2010.65

79. National Institute for Health and Clinical Excellence. Hypertension Management of hypertension in adults in primary care ­ NICE clinical guideline 18. ­London: Royal College of Physicians (UK); [Av. at: https://www.scritub.com/limba/engleza/health/Hypertension­Management­of­hyp1241821313.php]

80. Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed­Dose Combinations of Antihypertensive Agents: A Meta­Analysis. Hypertension. 2010;55(2):399–407. DOI: 10.1161/HYPERTENSIONAHA.109.139816

81. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics. 2001;23(8):1296–310. PMID: 11558866


Рецензия

Для цитирования:

Орлова Я.А., Курлыкина Н.В., Середенина Е.М. Тиазидные и тиазидоподобные диуретики в терапии артериальной гипертензии. Кардиология. 2019;59(11):84-94. https://doi.org/10.18087/cardio.2019.11.2653

For citation:

Orlova Y.A., Kurlykina N.V., Seredenina E.M. Thiazide and Thiazide-Like Diuretics in Therapy of Arterial Hypertension. Kardiologiia. 2019;59(11):84-94. (In Russ.) https://doi.org/10.18087/cardio.2019.11.2653

Просмотров: 4597


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)

Издательство ООО "КлинМед Консалтинг" ОГРН 1147746950779

121087 г. Москва, Береговой проезд, д.5 корп. 2, этаж 14, пом. 215
издательство КМК
тел.: (495) 211–6994
e-mail: magazine@ossn.ru

создано и поддерживается NEICON
(лаборатория Elpub)